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Pilot randomised trial of a brief intervention
for comorbid substance misuse in psychiatric
in-patient settings
Graham HL, Copello A, Griﬃth E, Freemantle N, McCrone P, Clarke L,
Walsh K, Stefanidou CA, Rana A, Birchwood M. Pilot randomised trial
of a brief intervention for comorbid substance misuse in psychiatric
in-patient settings.
Objective: This proof of principle study evaluated the eﬀectiveness and
feasibility of a brief motivational intervention, delivered in mental
health in-patient settings, to improve engagement in treatment for drug
and alcohol misuse.
Method: A randomised controlled trial using concealed
randomisation, blind, independent assessment of outcome at
3 months. Participants were 59 new adult admissions, to six acute
mental health hospital units in one UK mental health service, with
schizophrenia related or bipolar disorder diagnoses, users of
community mental health services and also misusing alcohol and/or
drugs. Participants were randomised to Brief Integrated Motivational
Intervention (BIMI) with Treatment As Usual (TAU), or TAU alone.
The BIMI took place over a 2-week period and encouraged
participants to explore substance use and its impact on mental
health.
Results: Fifty-nine in-patients (BIMI n = 30; TAU n = 29) were
randomised, the BIMI was associated with a 63% relative odds increase
in the primary outcome engagement in treatment [OR 1.63 (95% CI
1.01–2.65; P = 0.047)], at 3 months. Qualitative interviews with staﬀ
and participants indicated that the BIMI was both feasible and
acceptable.
Conclusion: Mental health hospital admissions present an
opportunity for brief motivational interventions focussed
on substance misuse and can lead to improvements in
engagement.
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Signiﬁcant Outcomes
• It is both feasible and acceptable for in-patient staﬀ to engage in-patient’s in brief motivational
interventions focussed on their substance misuse, whilst admitted to psychiatric hospitals. Staﬀ who
delivered the intervention found the short burst and targeted style a useful method of engaging
in-patients.
• The ﬁndings indicate that the brief motivational intervention, delivered during acute psychiatric
admission, led to improvements in engagement in substance misuse treatment.
• Whilst this is a challenging group of participants to engage, it is clear that it is possible to recruit
and retain participants from this client group and primary outcome data were available for 58, high-
lighting the advantage of a primary outcome measure based on assessment by care coordinators.
[Correction added on 6 May 2016, after ﬁrst online publication: Online open copyright updated]
298
Acta Psychiatr Scand 2016: 133: 298–309 © 2015 The Authors Acta Psychiatrica Scandinavica Published by John Wiley & Sons Ltd
All rights reserved
DOI: 10.1111/acps.12530
ACTA PSYCHIATRICA SCANDINAVICA
Limitations
• This was a pilot feasibility study, which supports the need for a larger trial.
• Specialist ‘dual diagnosis’ staﬀ delivering the intervention alongside in-patient staﬀ provided the lat-
ter with an additional level of available expertise, informal in-situ supervision and formed a bridge
with care coordinators in the community. However, the availability of such a resource is limited in
routine services and adds organisational complexity.
• Further research will need to test whether the intervention impacts signiﬁcantly to reduce subsequent
hospital admissions and substance misuse.
Introduction
Hospital admissions may present a natural window
of opportunity for in-patients to re-evaluate beha-
viours that might negatively impact on their health
and mental health (1–3). As acute symptoms of
mental ill health decline this period may be charac-
terised as a time of contemplation and a window
of increased awareness and insight into factors that
contributed to becoming mentally unwell and or
being admitted into hospital (4, 5). Research has
shown that, some individuals may ‘seal over’ the
experience, in an attempt to reduce emotional dis-
tress (6). That is, they may deny or minimise recent
mental health symptoms or experiences and pre-
cipitating factors, and as a result, lose awareness of
the triggers for becoming unwell (6). Sealing over
the experience of relapse was found to predict low
engagement with mental health services 6 months
after discharge for psychiatric in-patients (6). Drug
and alcohol misuse in those with severe mental
health problems is widespread (7–10). It is associ-
ated with poor engagement in treatment (11–13),
low motivation to change (14–16), increased
psychiatric hospital admissions (17) and impacts
negatively on the delivery of treatment and man-
agement of care during in-patient stays (18).
Among this client group, poor treatment engage-
ment is a barrier for change and positive treatment
outcomes (12, 16, 19, 20).
Of those admitted into psychiatric in-patient
facilities 22–44% have been found to have coexist-
ing alcohol or drug problems (18). However, drug
or alcohol problems and the role they may have
played in precipitating a psychiatric hospital
admission are not routinely addressed in such set-
tings. It is recommended that the clinical manage-
ment strategy of a psychiatric admission should
involve in-patient staﬀ who are trained in routine
assessment and treatment of substance misuse pro-
viding simple approaches to enhance motivation to
change substance use (18). Nonetheless, this con-
tinues to be a signiﬁcant gap in service provision,
re-admissions are high, outcomes for this group
remain poor (21, 22). There are equivocal ﬁndings
in trials of eﬀectiveness of long-term interventions
with psychosis and substance misuse (23). How-
ever, the evidence for brief motivational-based
interventions is encouraging (16, 24–28) and shows
promise in in-patient settings when delivered by
trained therapists (26, 29, 30).
Aims of the study
The current study sought to evaluate whether a
psychiatric hospital admission represents a natural
window of opportunity for individuals who misuse
substances to be routinely oﬀered treatment, by in-
patient staﬀ, to re-evaluate drug and alcohol use
and become aware of negative impacts on mental
health.
Material and methods
Study design and participants
The study was an open (rater blinded), prospective
randomised trial, analysed by intention to treat
(31). Intention to treat according to ICH E9 is the
principle that participants are analysed on the
basis of the group to which they were randomised
regardless of the treatment that they actually
received. The trial utilised concealed randomisa-
tion; blind, independent assessment of outcome at
3 months; characterisation of refusers and drop-
outs. Participants were randomised on a 1:1 basis,
to one of two experimental conditions: Brief Moti-
vational Intervention (BIMI) in addition to Treat-
ment As Usual (TAU); or TAU. Participants
recruited were as follows: adults aged 18 years or
above with an ICD-10 diagnosis of schizophrenia,
schizoaﬀective or delusional disorders (F20, 22, 23,
25, 28, 29); bipolar aﬀective disorders (F31); or
recurrent depressive disorder (F33.2) (32), service
users of community mental health services; new
admissions within the acute phase of severe mental
health problems; who were identiﬁed as misusing
alcohol and/or drugs over the past month based on
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a minimum score of 3 (abuse/dependent use based
on DSM-IV diagnostic criteria for substance-
related disorders) on the Clinicians Alcohol/Drugs
Use rating scale (CDUS/CAUS) over the past
3 months (32) and had a care coordinator in a
Community Mental Health Team. Participant’s
capacity to consent was established by the Respon-
sible Clinical Oﬃcer. Participants were recruited
from in-patient units, within a single UK, National
Health Service (NHS) Trust including eleven acute
wards and three Psychiatric Intensive Care Units
(PICUs), oﬀering a total of 202 beds over a 15-
month period. The trial received ethical approval
from the West Midlands – The Black Country
National Research Ethics Committee (12WM/
0369).
The primary hypothesis tested was that Brief
Integrated Motivational Intervention (BIMI) would
signiﬁcantly improve treatment engagement for
alcohol and drug misuse compared to TAU. The
secondary hypotheses were that those receiving the
BIMI would show greater readiness to change sub-
stance use behaviour when compared to those
receiving TAU and that the BIMI would be more
cost-eﬀective than the TAU due to reduced service
utilisation.
Eligible participants were identiﬁed by Research
staﬀ based on review of care records. A screening
measure was completed with care coordinators
conﬁrming trial eligibility. Within 2 weeks of
admission, once acute symptoms eased, eligible
participants were invited to participate. Written
information about the study was provided and
written consent obtained. A battery of assessments
was administered. Upon completion, participants
were randomly allocated to the intervention BIMI
group (in the context of TAU) or the TAU group
(the control group). Just prior to the 3-month data
collection meetings were scheduled for completion
of follow-up assessment battery by blind research-
ers. Participants were not paid for study participa-
tion.
Sample size
A power calculation was carried out based on a
previous study (27) using the primary outcome
measure: Substance Abuse Treatment scale
(SATs). Allocating 68 participants by a 1:1 strat-
egy between the treatment and control conditions
(34 participants per group) would have 90% power
(1-beta) to ﬁnd a diﬀerence of 1 point on the SATs
scale to be statistically signiﬁcant, using a conven-
tional two-sided alpha of 0.05. A 1-point diﬀerence
would be clinically important for participants and
mental health services as it would indicate
increasing levels of engagement in treatment and
addressing substance misuse (e.g. a shift from ‘Pre-
engagement’ to ‘Engagement’).
Randomisation
The trial used independent central randomisation
using a concealed process via e-mail. The research-
ers were blind to participant treatment group allo-
cation until all baseline, post-treatment and 3-
month follow-up quantitative assessments had
been completed. Researchers were unblinded once
the 3-month data collection had been completed.
Participants in the BIMI group then completed a
qualitative interview.
Trial Interventions
Brief integrated motivational intervention. The
BIMI, a ‘Brief Integrated Motivational Interven-
tion’, was oﬀered in the context of TAU, guided by
a manual designed for purpose, based on key
ingredients in the two early phases of Cognitive-
Behavioural Integrated Treatment (33) strategies
from Cognitive therapy for substance use (34) and
Motivational approaches (35). BIMI promoted a
conversational style to build good collaborative
relationships with participants working towards a
joint goal of ‘keeping participants from returning
to hospital’. The BIMI provided a 3-step frame-
work. The initial step provided participants with
personalised feedback of information gathered in
the baseline substance use assessment and high-
lighted potential impacts on health and mental
health. Participants were provided with tailored
psychoeducational material. The second step
aimed to help participants make decisions. Strate-
gies were aimed at: increasing awareness of per-
ceived ‘beneﬁts’ of use and ‘costs’ associated with
continued misuse; re-evaluation of positive beliefs
about substances; building awareness of how sub-
stance use and mental health interact and mainte-
nance cycles. The third step encouraged
participants to contemplate change and develop a
change plan based on a self-identiﬁed goal and
included strategies to cope with setbacks, cravings
and urges and develop social support for change.
Participants were oﬀered a Peer Mentor during the
second step of the intervention aiming to provide
ongoing support and solidarity for change.
The BIMI was delivered by in-patient unit staﬀ
trained as part of the study working alongside staﬀ
from a specialist ‘dual diagnosis’ Trust-wide ser-
vice, the COMPASS Programme (36). The BIMI
was delivered over a 2-week period for 4–6 sessions
lasting 15–30 min each. A ‘booster session’ was
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arranged to be delivered 1 month after completion.
The booster session aimed to consolidate motiva-
tion and transfer the skills from the BIMI to the
community and was provided by a member of the
specialist team and attended by the participant’s
community-based care coordinator. Staﬀ training
was delivered over 2 days and supported by a
treatment manual. Supervision of the BIMI was
provided by three of the Investigators. Group,
face-to-face or telephone supervision was deliv-
ered. During supervision, the standard of delivery
was regularly monitored and assessed for ﬁdelity
and adherence.
Treatment as usual
Treatment as usual was provided by nursing and
medical staﬀ on the mental health units in line
with in-patient policies and is regularly moni-
tored by the UK Care Quality Commission. It
included assessment and monitoring mental
state, provision of medication and stabilisation
of mental state.
Statistical methods
Analysis was carried out using SAS version 9.4
(SAS Institute, Cary NC, USA). The analysis
method for the primary outcome was a propor-
tional odds model. The proportional odds method
used included the pre- and postintervention peri-
ods (L1SATS and L3STATS), included a cumula-
tive log link function and multinomial error,
linked within a subject with a random intercept
term. Denominator degrees of freedom were
derived from the number of subjects. Models used
maximum likelihood with adaptive quadrature.
The appropriateness of the proportional odds
assumption was assessed using the Score Test. Sta-
tistical signiﬁcance was assessed using a conven-
tional two-sided alpha of 0.05. The secondary
outcomes were analysed using analogous gener-
alised mixed models with appropriate link func-
tions and error structures. The ITT principle was
used for all analyses. Missing data were excluded
as it would be inappropriate to impute it because it
is most plausibly missing not at random.
Cost-effectiveness evaluation
Participant contacts with staﬀ providing the inter-
vention were recorded as well as staﬀ supervision
time, and these were combined with unit costs (37).
Other service use was measured for the 3 months
prebaseline and over the postrandomisation period
using the Client Service Receipt Inventory (38).
This recorded use of primary and secondary health
and social care services. Sources of data included
Client self-report and where data could not be
obtained via self-report and/or speciﬁc information
was required (e.g. medication, appointments, dates
of hospital admission) this was gathered via the
service electronic medical records. Total service
costs were compared at baseline and over the pos-
trandomisation period, the latter adjusting for the
baseline costs. The EQ-5D (39) measure was used,
which is frequently used to produce quality-
adjusted life years as part of economic evaluations
(31). Cost data are frequently skewed, and a boot-
strap model was used which makes no assumption
about the underlying cost distribution.
Qualitative evaluation
Qualitative semistructured interviews with partici-
pants after the 3-month follow-up point sought to
assess satisfaction with the treatment received and
perceived processes of change, including helpful
aspects of the therapeutic process. A sample of
therapists was interviewed using a semistructured
interview, individually and in focus groups. These
were recorded, transcribed and thematic analysis
conducted, steps were taken to ensure reﬂexivity
(40). That is, attending systematically to the
context of knowledge construction by examining
concepts critically and aiming to eliminate assump-
tions and preconceptions aﬀecting interpretation
of ﬁndings. This was carried out through group
discussions between the analysts, with the wider
research team and checking the ﬁnal ﬁndings with
some participants (40).
Outcome measures
Primary outcome. The primary outcome was
engagement with substance misuse treatment
whilst in-patient and with community treatment
services at 3-month follow-up as reported by care
coordinators/primary clinician, using the SATS
(14, 32)a widely used measure with reported high
validity, reliability and test–retest reliability (14,
32). The Primary Clinicians assessed the level of
engagement in substance misuse treatment and
progress towards recovery from substance use
problems, based primarily on observable beha-
viours, on an 8-point hierarchical motivational
scale. The reporting timeframe was adapted to the
previous 3 months.
Secondary outcome measures. Readiness to
change. Current readiness to change alcohol and
drug use was assessed using the 19-item Stages of
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Change Readiness And Treatment Eagerness Scale
(41).
Motivation to change was measured by the
Importance-Confidence Ruler which is a global
assessment of motivation and conﬁdence to
change assessing two concepts underpinning
readiness to change (42); participants were also
asked to rate on a scale of 0–10 how important it
was to change the use of the primary substance
and how conﬁdent they were that they would suc-
ceed.
Drug use and alcohol use. Drug and alcohol use
was assessed using a number of complementary
measures. The number of days each substance had
been used in the past 30 days, and the average
amount of use of each drug on a using day was
assessed using section B of the Maudsley Addiction
Profile (43). The CDUS/CAUS was used as a
screening tool for inclusion, based on DSM-IV
diagnostic criteria for substance-related disorders,
and reliably used by primary Clinician’s to classify
severity of substance use among people with severe
mental health problems (32). The reporting time-
frame for the AUDIT both at baseline and post-
treatment was adapted to the previous 3 months.
The Severity of Dependence Scale was used to
screen for the severity of drug dependence (44–46).
The Alcohol Use Disorders Identification Test
(AUDIT) a well validated 10-item self-report ques-
tionnaire was used to investigate alcohol consump-
tion (47, 48).
Psychological functioning. Psychological function-
ing was assessed using three measures: Recovery
Style Questionnaire (RSQ) is a 39-item self-report
measure designed to assess two concepts of recov-
ery from mental health relapses; ‘Integration’ (i.e.
acknowledgement of, openness and attempts to
cope with the mental health problem), and ‘Seal-
ing-over’ (i.e. cognitive and behavioural attempts
at avoiding the diagnosis and experience of mental
health problems). It reliably enables four recovery
styles to be classiﬁed based on a continuum [i.e.
‘Integration’; ‘mixed picture in which integration
predominates’; ‘mixed picture in which sealing-
over predominates’ and ‘sealing-over’(49)]; Insight
Scale reliably assesses changes in levels of insight
in terms of perceived need for treatment (50);
HADS a 14-item self-report measure found to reli-
ably assess anxiety and depression (51, 52).
Results
A total of 60.67% (1345/2217) of in-patients
screened were using substances. However, 1286 did
not meet the other study criteria or declined to be
involved in the study. A total of 44%, (872/1976)
of in-patients were not misusing substances, or
their substance use was not recorded (Fig. 1).
Fifty-nine in-patients were recruited from 14 wards
(Acute n = 50; PICU n = 9) and randomised to
BIMI n = 30 or TAU n = 29. Table 1 shows base-
line characteristics of the participants who had a
mean age of 38.6 years, with a schizophrenia diag-
nosis, primarily misusing cannabis, or alcohol. In-
patients (N = 123) were approached regarding
involvement in the study, the characteristics of
those who consented compared to refusers
(n = 64) (52%) appeared similar in age, sex and
type of mental health team. All participants were
followed up for the primary outcome at 3 months,
one participant was withdrawn due to risks. Fifty
(85%) study participants were interviewed at
3-month follow-up.
The intervention
Twenty seven in-patient staﬀ from all wards and
six specialist staﬀ were trained to deliver the
BIMI, 12 in-patient staﬀ and ﬁve specialist staﬀ
actually delivered the MI. Twenty-one of the 30
(70%) participants in the BIMI group received
the intervention. The nine participants who did
not were discharged prior to the ﬁrst session
(n = 5), refused the intervention (n = 3) and sent
on home leave (n = 1). The mean exposure for
participants who received the intervention was
3.14 (SD 1.92) sessions (range 1–5 sessions). Mean
duration of sessions was 18.3 min (SD 4.90). The
average total mean duration of the intervention
was 57.6 min (SD 31.33). The booster session was
completed for nine (30%) of these participants.
Two participants received a session with a Peer
Mentor who aimed to provide ongoing support
and solidarity for change. The Peer Mentor pro-
vided some low-key social support and a listening
ear to help participants feel less isolated and more
connected to others during a challenging time and
to generally see how they were ﬁnding the inter-
vention.
Primary outcome
Engagement with substance misuse treatment. At
baseline, for both groups engagement could be
described as not having regular contact with an
assigned case manager. Both groups had shifted at
follow-up, indicating regular contacts with a case
manager and discussing substance use and showing
evidence of a reduction in use. The eﬀect of ran-
domisation to the BIMI group rather than TAU
302
Graham et al.
was described using the odds ratio where a value
greater than 1 indicates a beneﬁt for the interven-
tion. Two TAU SATs values were missing, one at
baseline the other at follow-up. The intervention
was associated with a 63% relative odds increase
in the SATs score, which is conventionally mod-
estly statistically signiﬁcant [OR 1.63 (95% CI
1.01–2.65; P = 0.047)] (Table 2). In supportive
analyses, the relationship between actual length of
stay in hospital and response to the intervention in
relation the primary outcome was examined. There
was no interaction between time in hospital and
treatment eﬀect.
Secondary outcome measures
Readiness to change. For the secondary outcome,
readiness to change, both groups remained in the
‘low’ readiness to change category for alcohol and
drugs at follow-up. No overall statistical analysis
was carried out for this readiness to change data,
due to missing data and the scores for alcohol and
Analysed (n = 30) Analysed (n = 28)
♦ Excluded from analysis (n = 1)
Reason (Withdrawn from trial due to 
risk)
Assessed for eligibility (n = 2217)
Excluded (n = 2158):
Did not meet criteria1 (n = 1976)
No substance misuse/not recorded (n = 872) 
Use substances but not other inclusion 
criteria (1104) 
Lost to follow-up at 3 months  (n = 0)
Allocated to intervention (n = 30)
♦ Received allocated intervention (n = 21)
♦ Did not receive allocated intervention (n = 9)
Discharged prior to intervention (n = 7)
Refused intervention (n = 2)
Lost to follow-up at 3 months (n = 1)
Withdrawn (n = 1)
Allocated to treatment as usual (n = 29)
Randomized (n = 59)
Declined to participate (n = 64): Other 2(n = 118)
Fig. 1. CONSORT diagram of trial proﬁle. 1Did not meet inclusion criteria: No substance misuse/Substance use not recorded
(n = 872), Use substances but not other inclusion criteria (n = 1104) (Inclusion criteria not met due to either, mental health, care co-
ordinator unavailable/unallocated, rating unavailable, discharged prior to rating, language, mental health capacity, care being trans-
ferred to or from another service). 2Other: includes previously consented (n = 6), previously refused (n = 15), previously withdrawn
(n = 1), discharged before rating (n = 30), unable to rate (n = 28), discharged before met (n = 32), not randomized – withdrawn
(n = 4), not randomized – discharged (n = 2).
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drug use could not be meaningfully combined.
Assessment of motivation to change indicated that
both groups at baseline similarly rated the Impor-
tance to change their substance use [BIMI = 6.77
(SD 3.23); TAU = 7.19(SD 3.58)] and Conﬁdence
to be able to change [BIMI = 8.12(SD 2.30);
TAU = 7.50(SD 2.94)]. There was very little varia-
tion between Importance [BIMI = 7.08(SD 3.74);
TAU = 6.89(SD 3.30)] and Conﬁdence
[BIMI = 8.15(SD 2.19); TAU = 8.02(SD 2.83)]
scores across time and between groups.
Substance use. Number of days substances
used. The number of days in the past 30 in which
the primary substance consumed was available for
50 subjects at baseline and follow-up. Both groups
reduced number of days they used by more than
half (Table 3). There was no evidence of an eﬀect
of randomised treatment on the number of days
using the primary substance [Relative risk 1.02
(95% CI 0.82–1.26; P = 0.85)] (Table 2).
In supportive analysis, the amount of substance
used was explored. At 3-month follow-up, 15 par-
ticipants reported not having used any substances
in the past 30 days; 10 of whom were in the BIMI
group compared to 5 in TAU (Table 3). The num-
ber of substances used by the BIMI group reduced
on average by 0.34 or about a third of a substance
when compared to the TAU group (Table 2).
However, the eﬀect was not signiﬁcant [OR 0.66
(95% CI 0.33–1.33; P = 0.24)].
Severity and impact of substance use. Mean baseline
scores for the primary substance used for both
groups, as rated by the care coordinator, were cat-
egorised as ‘abuse’ in the previous 3 months
(Table 4). Mean AUDIT scores for the TAU and
BIMI group met the ‘possible dependence’ cate-
gory at baseline. At 3-month follow-up, these
mean scores were lower and were within the
Table 1. Baseline characteristics of participants
TAU (n = 29) BIMI (n = 30)
Age
Mean (SD) 37.69 (11.11) 39.5 (11.12)
Sex (%)
Male 25 (86.2) 25 (83.3)
Diagnosis (%)
Schizophrenia 19 (65.5) 17 (56.7)
Schizoaffective disorder 2 (6.9) 3 (10)
Psychosis 1 (3.4) 0 (0)
Bipolar affective disorder 7 (24.1) 10 (33.3)
Primary substance (%)
Alcohol 11 (37.9) 12 (40)
Cannabis 13 (44.8) 14 (46.7)
Crack 0 (0) 1 (3.3)
Cocaine 2 (6.9) 0 (0)
Methadone 1 (3.4) 0 (0)
Legal Highs 2 (6.9) 2 (6.7)
Diamorphine 0 (0) 1 (3.3)
Ethnic origin (%)
White British 15 (51.7) 7 (23.3)
White Irish 2 (6.9) 4 (13.3)
Asian Indian 2 (6.9) 0 (0)
Asian Pakistani 1 (3.4) 4 (13.3)
Asian Bangladeshi 1 (3.6) 0 (0)
Asian Other 1 (3.4) 1 (3.3)
Black Caribbean 4 (13.8) 8 (26.7)
Black African 2 (6.9) 0 (0)
Black Other 0 (0) 1 (3.3)
Mixed Caribbean 0 (0) 5 (16.7)
Mixed African 1 (3.4) 0 (0)
Housing status (%)
Live alone 16 (55.2) 16 (53.3)
With parents or guardian 5 (17.2) 9 (30)
With partner 3 (10.3) 0 (0)
Other 5 (17.2) 5 (16.7)
Table 2. Difference in Substance Abuse Treatment scale (SATs), number of substances used, days using and HADS at 3-month follow-up by randomised condition, conditional on
baseline assessment
Outcome Odds Ratio† (95% CI) Relative Risk‡ (95% CI) Difference in means§ (95% CI) P value¶
SATs 1.63 (1.01–2.65) – – 0.047*
Number of substances used 0.66 (0.33–1.33) – – 0.240
Number of days using primary substance – 1.02 (0.82–1.26) – 0.854
HADS
Anxiety – – 0.80 (3.93–2.34) 0.611
Depression – – 1.89 (4.51 to 0.74) 0.156
Insight Scale
Awareness of symptoms – – 0.03 (0.70 to 0.75) 0.944
Awareness of illness – – 0.25 (0.42 to 0.93) 0.459
Need for treatment – – 0.09 (0.65 to 0.84) 0.802
Total – – 1.03 (0.49 to 2.54) 0.178
†Mixed proportional odds model.
‡Poisson mixed model
§Gaussian mixed model
¶Two-tailed.
*P < 0.05.
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‘increasing risk category’. Mean SDS scores across
time and groups were all above a score of 4 which
suggested a continued ‘level of dependence’.
Psychological functioning. Anxiety and depres-
sion. Analysis of the diﬀerence in the HADS Anx-
iety and Depression Scores by randomised group,
accounting for baseline values, indicated no evi-
dence of a treatment eﬀect on HADS Anxiety (Dif-
ference in means 0.80 [95% CI 3.93–2.34;
P = 0.611)]. The HADS Depression, although not
signiﬁcant, was in line with a modest eﬀect on that
outcome suggesting that the TAU had higher
depression scores (Diﬀerence in means 1.89 [95%
CI 4.51 to 0.74; P = 0.156)] (Table 2).
Style of recovery from mental health problems. Base-
line mean scores on the RSQ descriptively classi-
ﬁed the TAU group as adopting a ‘mixed picture
in which integration predominates’ style of recov-
ery from mental health problems [66.54 (SD
15.28)], and the BIMI group as adopting an ‘inte-
gration’ style [71.14 (SD 13.37)]. At 3-month fol-
low-up, both groups were classiﬁed as ‘integration’
(TAU = 70.74 (SD 70.74); BIMI = 71.15(SD
18.97), suggesting that both groups had an
acknowledgement of and were making attempts to
cope with their mental health problems. Due to the
amount of missing data, no further analysis was
conducted.
Insight in mental health problems. Awareness of
symptoms and of illness mean scores indicated
‘poor insight’ over time in both TAU groups at
baseline and follow-up. Need for treatment mean
scores increased over time for both groups suggest-
ing ‘good insight’ into need for treatment. The dif-
ference in means implied a beneﬁt for the
intervention. Whilst there were no signiﬁcant dif-
ferences, all values pointed towards a beneﬁt from
the BIMI (Table 2).
Cost-effectiveness evaluation
For the secondary outcome of cost-eﬀectiveness,
service use in the period prior to baseline was rela-
tively similar between the two groups. All partici-
pants were in-patients during the baseline period
and all but one were also in-patients during the
postrandomisation period (one participant in the
BIMI group went on home leave on the day of ran-
domisation). Although we do not test for diﬀer-
ences for individual services, it was observed that
during the postrandomisation period there was a
greater number of participants in contact with psy-
chiatrists in the BIMI group (BIMI n = 19; TAU
n = 13) and more participants in contact with
assertive outreach teams (BIMI n = 7; TAU
n = 1). At baseline, the number of days in hospital
was similar between the groups (BIMI = 13.4 (SD
7.9); TAU=14.5 (SD 9.7). During the post-rando-
misation period, in-patient days were slightly
higher in the BIMI group (BIMI = 45.3 (SD 35.1);
TAU = 35.8 (SD 30.8). The mean cost of deliver-
ing the intervention was £72 (SD £66). The total
mean cost of services used postrandomisation by
the TAU and BIMI group was £15 698 (SD
£12 632) and £18 651 (SD £15 580) respectively.
Adjusting for baseline costs, the BIMI group had
costs that were on average £3279 higher postran-
domisation than the TAU group (95% CI, £3933
to £10 876). One participant in the BIMI group
was an outlier in number of days of in-patient care
during the postrandomisation period. When they
were removed, the mean cost for the BIMI group
was £16 825 (SD £12 159). The EQ5D-5L scores
were similar between the two groups.
Qualitative evaluation
Two focus groups (n = 7) and ﬁve individual inter-
views were conducted with staﬀ who delivered the
BIMI. Twenty-one participants who received
the intervention were interviewed at follow-up.
Table 3. Substance Use in past 30 days at baseline and follow-up
BIMI TAU
Baseline
(n = 30)
Follow-up
(n = 26)
Baseline
(n = 29)
Follow-up
(n = 24)
Number of substances
None 0 10 0 5
One 14 10 18 16
Two 12 6 7 3
Three 4 0 3 0
Four 0 0 1 0
Number of days used
Mean (SD) 21.48 (11.00) 9.25 (10.82) 21.23 (9.68) 9.31 (11.86)
Table 4. Severity and impact of primary substance at baseline and 3-month follow-
up
TAU BIMI
Baseline Follow-up Baseline Follow-up
Alcohol (CAUS) N = 11 N = 11 N = 12 N = 12
Mean (SD) 3.27 (0.65) 2.18 (.98) 3.42 (0.67) 2.25 (1.22)
Drugs (CDUS) N = 18 N = 17 N = 18 N = 18
Mean (SD) 3.28 (0.46) 2.41 (1.06) 3.33 (0.49) 1.89 (0.90)
Alcohol Use
(AUDIT)
N = 11 N = 11 N = 12 N = 9
Mean (SD) 20.00 (8.14) 13.09 (7.92) 22.00 (7.76) 15.11 (7.71)
Drug Use (SDS) N = 18 N = 13 N = 18 N = 14
Mean (SD) 5.11 (4.93) 5.31 (3.68) 4.56 (4.23) 4.64 (4.18)
305
Comorbidity in psychiatric hospitals
Qualitative data revealed that participants and
staﬀ found the BIMI both feasible and acceptable
when delivered as part of routine care on in-patient
wards. Whilst most participants reported on posi-
tive non-speciﬁc factors of the intervention, such
as ‘staﬀ giving time’ and ‘going out of their way’,
several participants identiﬁed that the intervention
allowed them to recognise the amount of sub-
stances they were using, the pros and cons/eﬀects
of their use on them or their mental health, as well
as developing new coping strategies and tech-
niques. For in-patient staﬀ and the specialist prac-
titioners, the targeted, motivational style of the
intervention and the brevity of the sessions were
found to be useful to engage patients in discussions
about their substance use. There were mixed views
about the timing of the intervention and how well
it worked when in-patients were acutely unwell;
other issues included the practicalities of joint
working between in-patient and community-based
staﬀ; and conﬂict with duties on the ward.
Discussion
The intervention was associated with an improve-
ment in engagement in treatment, the primary out-
come, which was modestly statistically signiﬁcant
providing some support for the principal hypothe-
sis in line with ﬁndings in out-patient settings (27).
During the postrandomisation period, there were
greater rates of contacts with psychiatrists and
assertive outreach teams among in-patients who
received the intervention. A shift was observed
from irregular to regular contacts with care coordi-
nators, discussing substance use. Both groups fell
into the ‘low’ readiness to change category at fol-
low-up, and there was no signiﬁcant diﬀerence in
the reduction in the number of days on which the
primary substance was used between groups. How-
ever, both groups reported a reduction by more
than half in the number of days they used their pri-
mary substance over the past 30 days at 3-month
follow-up. These changes in substance use noted in
both groups are not an uncommon ﬁndings in
studies evaluating motivational-based interven-
tions. A number of explanations have been oﬀered
including the natural ﬂuctuations in coexisting
mental health and substance misuse and the period
before an admission being associated with greater
amounts of substance use resulting in relative
improvement that may not necessarily reﬂect
longer term improvements; also it has been sug-
gested that the baseline assessment of both groups
may have a motivational eﬀect (53–55). Some
exploratory non-signiﬁcant ﬁndings that warrant
investigation in a larger trial are reductions in the
number of substances used. A study by Baker and
colleagues carried out in in-patient settings simi-
larly found that BIMIs had the potential to have a
modest, short-term impact on poly-drug use (56).
Tobacco smoking was not assessed in the current
study; however, this would be an important con-
sideration within future research due to its preva-
lence and impacts in this population.
The study aimed to assess the feasibility and
acceptability of delivering a brief integrated moti-
vational intervention to in-patients as part of rou-
tine care on the wards. The recruitment rate in the
current study was 50%, which was expected
among this group of service users who have been
historically described as ‘diﬃcult to engage’ (11–
14, 27). However, 85% of participants were
retained in the study at follow-up and 70% of par-
ticipants engaged in the BIMI with a good level of
exposure to it. In-patients described the interven-
tion as helpful enabling them to: have an opportu-
nity to talk to in-patient staﬀ, recognise the
amount of substances they were using and the
eﬀects of their use on them including their mental
health. Developing new coping strategies and tech-
niques was also helpful. This study indicates that it
is feasible and acceptable to engage and retain in-
patients, with severe mental health problems from
a diverse range of ethnic origins, who are poorly
engaged in treatment and misusing a range of sub-
stances in a brief intervention for substance mis-
use, whilst they are on a psychiatric wards. There
was improved awareness in both groups over time
of the need for mental health treatment and a posi-
tive shift to a more integrating style of recovery
from mental health problems which has been asso-
ciated with improved engagement in treatment
over time (6). The intervention was relatively low
cost, and no signiﬁcant diﬀerences were observed
in costs between the two groups. The rate of sub-
stance use in the in-patient sample was 61%. How-
ever, despite the reported rates prevalence of
substance misuse among those with severe mental
health problems in the literature and in the current
study, a number of in-patients in the current study
were unable to be included for a number of rea-
sons. Key factors appeared to be whether informa-
tion about substance use was reported and how it
was reported and the stringent study inclusion cri-
teria needed due to the nature of a randomised
controlled trial. These factors have important
implications for clinical practice and a further trial.
Some of the eligible in-patients who refused to par-
ticipate were poorly engaged with services and with
their in-patient care and treatment; some were
reluctant or suspicious of engaging in a research
study to discuss their substance use. Future
306
Graham et al.
research might also consider strategies to increase
the participation rate among eligible in-patients,
including payment for participation and interven-
ing earlier on during an admission.
Unlike previous studies (26, 29, 30), the current
study utilised routine in-patient staﬀ to deliver the
intervention. They reported that the short burst
and targeted style of the intervention was a useful
method of engaging in-patients in discussions
about drug and alcohol use. However, they felt
that the timing (i.e. when such an intervention is
delivered) was important due to the mental state of
in-patients on acute wards. Similarly participants
felt that sometimes they did not have the ‘head-
space’ and so the timing of the intervention
appears important. The qualitative ﬁndings high-
light that a shift in the clinical management strat-
egy on wards would be needed for such brief
interventions to become embedded into routine
practice (57, 58). The literature on in-patient psy-
chiatric treatment has highlighted the need for
‘protected time’ for staﬀ to deliver therapeutic
interventions as a routine part of their in-patient
work (59–61).
Specialist ‘dual diagnosis’ staﬀ delivering the
intervention alongside routine in-patient staﬀ pro-
vided an additional level of available expertise and
informal supervision in-situ. However, the avail-
ability of such a specialist resource is limited and
adds another layer of organisational complexity.
Nonetheless, the recommendations from other
studies for comorbid severe mental health and sub-
stance misuse problems are that brief interventions
are best provided within the context of a compre-
hensive package of ongoing integrated treatment
(27, 62), and the specialist staﬀ were able to form a
bridge with care coordinators in the community.
In future trials, the BIMI may beneﬁt from evalua-
tion as part of a comprehensive package of inte-
grated treatment so that positive changes in
engagement can be built upon in community ser-
vices postdischarge.
This proof of principle study attempted to test
the BIMI, method and measures in an in-patient
setting, and there are aspects that would require
reﬁnement for further studies. There were recruit-
ment challenges; the original protocol aimed for
recruitment of 68 participants, in the event we
recruited 59. Whilst a challenging group of partici-
pants to engage, it is clear that it is possible to
recruit and retain participants from this client
group and primary outcome data were available
for 58 highlighting the advantage of a primary out-
come based on an assessment by care coordinators.
However, although these primary Clinicians would
have been blind at the baseline and 2-week ratings,
potentially they were not at the 3-month rating for
those in the intervention arm. This is a limitation
of the study that may have introduced bias. In
addition, a rating of this nature provided by the
Primary Clinician working with the client might be
inﬂuenced by the therapeutic alliance. Measuring
motivation to change raised a number of chal-
lenges, including the sensitivity of the measures to
diﬀerentiate between those who are abstinent or
have made changes in substance use compared to
those who are precontemplators. The low uptake
of Peer mentors requires further consideration in
future research. The low number of female in-
patients included in the study may well reﬂect that
coexisting severe mental health, and substance mis-
use is more common among men and less prevalent
among females. It is also questionable whether an
improvement in costs and health-related quality of
life over a 3-month time period would be found. A
future trial should include a suﬃciently long fol-
low-up to explore cost changes over a prolonged
period. In particular, long enough to detect diﬀer-
ences in readmission rates and assess changes in
substance misuse. However, this pilot feasibility
study suggests that an acute psychiatric hospital
admission may present a ‘teachable moment’ simi-
lar to that identiﬁed in physical health settings (1,
63); that is a natural window of opportunity for in-
patient staﬀ to routinely engage in-patients in
BIMIs focussed on alcohol and drug use. The
intervention is feasible and represents a simple,
low cost and easy to implement approach, how-
ever, timing is key.
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